Abstract
Thioridazine is a phenothiazine drug which has previously been extensively used for its antipsychotic properties as it is associated with a low risk of extra-pyramidal side-effects. There is good evidence to suggest that, in common with other phenothiazine drugs, thioridazine has important anti-microbial activity and is a potential candidate for development as an anti-microbial drug against multi-resistant organisms, including drug-resistant strains of Mycobacterium tuberculosis. The clinical pharmacology and toxicity profile of thioridazine are reviewed in this article and the implications for future drug development along with the patent are discussed.
Keywords: Antimicrobial, cardiotoxicity, extra-pyramidal syndrome, QT prolongation, thioridazine, METABOLISM OF THIORIDAZINE, CYP2C19, Anti-psychotic activity, arrhythmogenic effect
Recent Patents on Anti-Infective Drug Discovery
Title: Thioridazine: The Good and the Bad
Volume: 6 Issue: 2
Author(s): Ruben H.K. Thanacoody
Affiliation:
Keywords: Antimicrobial, cardiotoxicity, extra-pyramidal syndrome, QT prolongation, thioridazine, METABOLISM OF THIORIDAZINE, CYP2C19, Anti-psychotic activity, arrhythmogenic effect
Abstract: Thioridazine is a phenothiazine drug which has previously been extensively used for its antipsychotic properties as it is associated with a low risk of extra-pyramidal side-effects. There is good evidence to suggest that, in common with other phenothiazine drugs, thioridazine has important anti-microbial activity and is a potential candidate for development as an anti-microbial drug against multi-resistant organisms, including drug-resistant strains of Mycobacterium tuberculosis. The clinical pharmacology and toxicity profile of thioridazine are reviewed in this article and the implications for future drug development along with the patent are discussed.
Export Options
About this article
Cite this article as:
H.K. Thanacoody Ruben, Thioridazine: The Good and the Bad, Recent Patents on Anti-Infective Drug Discovery 2011; 6 (2) . https://dx.doi.org/10.2174/157489111796064588
DOI https://dx.doi.org/10.2174/157489111796064588 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Immunopotentiation for Bacterial Biodefense
Current Topics in Medicinal Chemistry Nanosuspensions of Poorly Water Soluble Drugs Prepared by Top-down Technologies
Current Pharmaceutical Design Using Biologic Agents in Pediatric Rheumatologic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies
Current Topics in Medicinal Chemistry Toll-Like Receptor Signaling Mechanisms Involved in Dendritic Cell Activation: Potential Therapeutic Control of T Cell Polarization
Current Pharmaceutical Design <i>In Vivo</i> Anti-Candida Activity of <i>Artemisia herba alba</i> asso and <i>Citrus aurantium</i> Extracts Formulated in Different Ointments
Anti-Infective Agents Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review
Reviews on Recent Clinical Trials Structure-and-Mechanism-Based Design and Discovery of Type II Mycobacterium Tuberculosis Dehydroquinate Dehydratase Inhibitors
Current Topics in Medicinal Chemistry Dendritic Cells: A Double-Edge Sword in Atherosclerotic Inflammation
Current Pharmaceutical Design Αlpha-2 Adrenergic and Opioids Receptors Participation in Mice Gastroprotection of Abelmoschus esculentus Lectin
Current Pharmaceutical Design An Overview of Novel Coronavirus Disease 2019: A Global Havoc
Coronaviruses A Review of Recent Advancements in Anti-tubercular Molecular Hybrids
Current Medicinal Chemistry Molecular Targets for Design of Novel Inhibitors to Circumvent Aminoglycoside Resistance
Current Drug Targets Inhaled Biologics: From Preclinical to Product Approval
Current Pharmaceutical Design Vitamin D among Patients of Pulmonary and Extrapulmonary Tuberculosis: A Prospective Case-control Study
Current Respiratory Medicine Reviews Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Natural Products: Key Prototypes to Drug Discovery Against Neglected Diseases Caused by Trypanosomatids
Current Medicinal Chemistry Multiplex PCR is a Rapid, Simple and Cheap Method for Direct Diagnosis of M. tuberculosis from Sputum Samples
Infectious Disorders - Drug Targets QSAR Study of Androstenedione Analogs as Aromatase Inhibitors
Letters in Drug Design & Discovery